Physician_Profile_ID,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID,Total_Amount_of_Payment_USDollars,Date_of_Payment,Form_of_Payment_or_Transfer_of_Value,Record_ID,Name_of_Associated_Covered_Drug_or_Biological1,Name_of_Associated_Covered_Drug_or_Biological2,Name_of_Study,Research_Information_Link,Context_of_Research
1171097,"Merck Sharp & Dohme Corporation",NJ,100000000053,81.60,10/30/2013,"In-kind items and services",24481112,"EMEND for Injection","","A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In","",""
1171097,"Merck Sharp & Dohme Corporation",NJ,100000000053,81.60,11/25/2013,"In-kind items and services",24481114,"EMEND for Injection","","A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In","",""
1171097,"Merck Sharp & Dohme Corporation",NJ,100000000053,81.60,11/25/2013,"In-kind items and services",24481115,"EMEND for Injection","","A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In","",""
1171097,"Merck Sharp & Dohme Corporation",NJ,100000000053,81.60,11/25/2013,"In-kind items and services",24481113,"EMEND for Injection","","A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In","",""
1171097,"Merck Sharp & Dohme Corporation",NJ,100000000053,73.50,11/25/2013,"In-kind items and services",24481111,"EMEND for Injection","","A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In","",""
1171097,"Merck Sharp & Dohme Corporation",NJ,100000000053,48.47,10/30/2013,"In-kind items and services",24481193,"EMEND for Injection","","A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In","",""
1171097,"Merck Sharp & Dohme Corporation",NJ,100000000053,13.60,10/30/2013,"In-kind items and services",24481191,"EMEND for Injection","","A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In","",""
1171097,"Merck Sharp & Dohme Corporation",NJ,100000000053,13.60,10/30/2013,"In-kind items and services",24481192,"EMEND for Injection","","A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In","",""
